Pharmaceutical testing company Inotiv faces an investigation into whether its monkey-sourcing practices may have violated the US foreign bribery law.
The SEC has sent Inotiv a request for documents and information relating to the company’s and several subsidiaries’ importation of “non-human primates” from Asia, including whether its practices comply with
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day